Agilent Technologies and GE Healthcare join WIN consortium
22 Feb 2011
The Worldwide Innovative Networking in Personalized cancer
medicine (WIN) Consortium is a joint initiative from the Institut
Gustave Roussy (IGR, France) and the University of Texas MD Anderson
Cancer Center (MDACC, USA).
The founding members are 17 academic cancer centres across all
continents, National Breast Cancer Foundation, Sage Bionetworks and
three major industry partners Agilent Technologies, GE Healthcare,
and Life Technologies.
“Its aim is to address the challenge of increasing the efficacy
of cancer healthcare globally through personalized therapy and early
diagnostics, in diverse populations from North and South America,
Europe, Asia, Africa and the Middle East,” says Dr John Mendelsohn,
Chairman of WIN.
“We are extremely proud to participate to the WIN consortium, and
will actively participate to make this project a success,” said Mark
Vossenaar of Agilent), Robert Dann of GE Healthcare and Martin Naley
of Life Technologies in a joint statement.
The WIN Consortium has also announced the constitution of its
independent Scientific Advisory Board, chaired by Dr Richard L
Schilsky and constituted by worldwide experts: Leroy Hood, Phillip
Febbo, Daniel Hayes, David Tuveson, Guido Kroemer, Laura Van T Veer,
Gary Rosner, Yves Lussier, Julio Celis, Manfred Schmitt and Ji
Zhang. The Scientific Advisory Board has already started selecting
the first scientific projects of WIN.
“Our overarching goals are to achieve more rapid and efficient
translation of groundbreaking personalized cancer medicine
discoveries into the standards for clinical care, to significantly
improve the outcomes and quality of life of cancer patients, with a
very ambitious goal of generating the first relevant study results
within 3-5 years.” says Dr Richard L. Schilsky, Chairman of WIN SAB.
The 3rd WIN symposium, which will be held on 6-8 July, will be “a
forum for open discussion in which your expertise and input is
crucial. It is also a unique opportunity to hear more about WIN and
consider taking an active part in this challenging project.” says
Dr. Vladimir Lazar, Chief Operating Officer of WIN.
For more information on the symposium see: